Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis

2012 ◽  
Vol 10 (12) ◽  
pp. 2599-2601 ◽  
Author(s):  
M. CARRIER ◽  
A. A. KHORANA ◽  
J. I. ZWICKER ◽  
G. H. LYMAN ◽  
G. LE GAL ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Cancer Clinical Trials ◽  
Standardized Reporting

Signaling inhibition with radiation in colorectal cancer: Clinical trials

2003 ◽  
Vol 30 (3 Suppl 6) ◽  
pp. 56-67 ◽  
Author(s):  
W. Gillies McKenna ◽  
Ruth J. Muschel ◽  
Anjali Gupta ◽  
Stephen Hahn ◽  
Eric J. Bernhard
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Cancer Clinical Trials

Treatment and secondary prevention of venous thromboembolism in cancer patients

2012 ◽  
Vol 03 (03) ◽  
pp. 121-125
Author(s):  
I. Pabinger ◽  
C. Ay
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
New Oral Anticoagulants ◽  
Phase Iii ◽  
Patients With Cancer ◽  
Potential Use

SummaryCancer is a major and independent risk factor of venous thromboembolism (VTE). In clinical practice, a high number of VTE events occurs in patients with cancer, and treatment of cancerassociated VTE differs in several aspects from treatment of VTE in the general population. However, treatment in cancer patients remains a major challenge, as the risk of recurrence of VTE as well as the risk of major bleeding during anticoagulation is substantially higher in patients with cancer than in those without cancer. In several clinical trials, different anticoagulants and regimens have been investigated for treatment of acute VTE and secondary prophylaxis in cancer patients to prevent recurrence. Based on the results of these trials, anticoagulant therapy with low-molecular-weight heparins (LMWH) has become the treatment of choice in cancer patients with acute VTE in the initial period and for extended and long-term anticoagulation for 3-6 months. New oral anticoagulants directly inhibiting thrombin or factor Xa, have been developed in the past decade and studied in large phase III clinical trials. Results from currently completed trials are promising and indicate their potential use for treatment of VTE. However, the role of the new oral thrombin and factor Xa inhibitors for VTE treatment in cancer patients still has to be clarified in further studies specifically focusing on cancer-associated VTE. This brief review will summarize the current strategies of initial and long-term VTE treatment in patients with cancer and discuss the potential use of the new oral anticoagulants.

scholarly journals Publication Rate and Characteristics of Lung Cancer Clinical Trials

2019 ◽  
Vol 2 (11) ◽  
pp. e1914531
Author(s):  
Ghassan Al-Shbool ◽  
Hira Latif ◽  
Saira Farid ◽  
Shuqi Wang ◽  
Jaeil Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Publication Rate ◽  
Cancer Clinical Trials

Prophylaxis of Venous Thromboembolism Following Orthopedic Surgery: Mechanical and Pharmacological Approaches and the Need for Extended Prophylaxis

1999 ◽  
Vol 82 (08) ◽  
pp. 918-924 ◽  
Author(s):  
R.D. Hull ◽  
G.F Pineo
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Orthopedic Surgery ◽  
Total Joint Replacement ◽  
Case Series ◽  
Pharmacological Agents ◽  
Thrombotic Disease ◽  
Vein Thrombosis ◽  
Major Orthopedic Surgery ◽  
Mechanical Devices

IntroductionMajor orthopedic surgery, particularly total joint replacement or hip fracture, represents a high risk of future development of postoperative venous thromboembolism and warrants the routine use of prophylaxis with either mechanical devices or pharmacological agents. The aim of prophylaxis is to prevent fatal pulmonary embolism (PE) and the morbidity of deep vein thrombosis (DVT), particularly the development of post-thrombotic syndrome. Patterns of clinical practice, with respect to the prevention of venous thromboembolism and the appropriate use of anticoagulants for the treatment of thrombotic disease, have been strongly influenced by recent consensus conferences.1,2 Rules of evidence for assessing the literature have been applied to all recommendations regarding the prevention and treatment of thrombotic disease. These results were extrapolated using evidence gleaned from major clinical disorders and are based only on nonrandomized clinical trials or case series.1-3 Data from a large number of Level I clinical trials in patients undergoing orthopedic surgery have provided answers to many of the questions regarding prophylaxis of venous thromboembolism. In this review, we will discuss the prevention of venous thromboembolism following orthopedic surgery and discuss some of the controversial issues where further studies are required.

Sign in / Sign up

Export Citation Format

Share Document